Keyphrases
Visceral Leishmaniasis
94%
Trypanosoma Cruzi (T. cruzi)
52%
Chagas Disease
50%
Drug Target
46%
Leishmania Donovani
37%
Preclinical Candidate
29%
Naphthyridine
22%
Cyclin-dependent Kinase 12
22%
Kinetoplastid
22%
Protease Inhibitors
22%
Mode of Action
20%
Mouse Model
20%
Protozoan Parasites
20%
Metabolic Stability
19%
In Vivo Efficacy
17%
Amino
16%
Pyrazolo
16%
Proteasome Inhibition
15%
Antileishmanial Activity
14%
Active Compounds
13%
Parasitic Infection
13%
Current Treatment
13%
Diamino
12%
Leishmania
12%
Molecular Targets
11%
Pyrimidine
11%
Potential Treatments
11%
In Vivo Activity
11%
Compound 8
11%
Methionyl-tRNA Synthetase
11%
Disubstituted piperazines
11%
Pharmacological Validation
11%
Allosteric Binding Site
11%
Qi Site
11%
Publication Process
11%
Material Difference
11%
Cross-coupling Reaction
11%
1,6-Naphthyridines
11%
Preclinical Development
11%
1,2,3-Triazole-4-carboxamide
11%
Benznidazole
11%
Nifurtimox
11%
Guided Synthesis
11%
Resin
11%
Chelator
11%
Pyridazinone
11%
Human African Trypanosomiasis
11%
Cyclin-dependent Kinase
11%
Antifolate
11%
Chemical Proteomics
11%
Pharmacology, Toxicology and Pharmaceutical Science
Visceral Leishmaniasis
100%
Trypanosoma Cruzi
61%
Chagas Disease
52%
Proteasome
37%
Cyclin Dependent Kinase
33%
Leishmania donovani
28%
Mouse Model
26%
Protozoon
25%
Infection
24%
Proteasome Inhibitor
24%
Naphthyridine Derivative
22%
Disease
21%
Leishmania
19%
Divalent
16%
Pharmacokinetics
16%
Parasitosis
16%
Structure Activity Relationship
15%
Kinetoplastida
14%
Drug Discovery
13%
Binding Site
12%
Carboxamide
12%
Piperazine Derivative
11%
Methionine Transfer RNA Ligase
11%
Amastigote
11%
Amitrole
11%
Pyrimidine Derivative
11%
Pharmaceutical Chemistry
11%
Chelating Agent
11%
Side Effect
11%
Antitrypanosomal
11%
Nagana
11%
Benznidazole
11%
Nifurtimox
11%
Transition Element
11%
Molecular Target
11%
Cytochrome B
11%
Cryo-Electron Microscopy
11%
Bovine
7%
Tolerability
5%
Therapeutic Window
5%
Sulfonamide
5%
Piperazine
5%
Coenzyme Q - Cytochrome C Reductase
5%
Enzyme Inhibition
5%
Antitarget
5%
Neglected Disease
5%
High-Content Screening
5%
Zinc Ion
5%
Metal Ion
5%
High-Throughput Screening
5%
